Case based discussion- Adalimumab in Rheumatology

Speciality: Rheumatology


Speaker:

Dr. Kunal Chandwar (Speaker) | Consultant Rheumatology

Dr. Juhi Dixit (Speaker) | Consultant Rheumatology

Dr. Digvijay Ekbote (Moderator) | Consultant Rheumatology

Dr. Dogga Prasanna (Speaker) | Consultant Rheumatology

Dr. Kriti Kishore (Speaker) | Consultant Rheumatology

Description:

A warm welcome to all the medical professionals in this interesting session on Case based discussion- Adalimumab in Rheumatology.
Case-based discussions on the use of Adalimumab in rheumatology highlight its significant impact on managing various inflammatory conditions, such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). In clinical practice, individual cases illustrate how Adalimumab, a TNF-alpha inhibitor, can dramatically reduce symptoms like pain, swelling, and stiffness, leading to improved patient quality of life. For instance, patients with severe RA often report substantial relief and enhanced joint function within weeks of initiating Adalimumab therapy, underscoring its rapid and effective action.
Safety considerations are integral to case discussions, as real-world patient experiences provide insights into managing potential adverse effects. Common side effects, such as injection site reactions and increased susceptibility to infections, require vigilant monitoring and patient education. Serious but less frequent risks, including reactivation of latent tuberculosis or development of autoimmune conditions, necessitate thorough pre-treatment screening and ongoing evaluation. Case studies also emphasize the importance of individualized treatment plans, where the benefits of Adalimumab are weighed against potential risks, allowing rheumatologists to tailor therapy to each patient's unique clinical profile.
Therefore, get an overall knowledge of case based discussion- adalimumab in rheumatology.See More Webinars @ Hidoc Webinars




Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

A hint regarding aspirin, the connection to colon cancer, the approval of the new Lutathera, artificial intelligence, and electronic records.

2.

Study: One-week breast cancer radiotherapy proven as safe and effective as standard three-week treatment

3.

Racial differences seen in epigenetic age acceleration in childhood cancer survivors

4.

ASTRO Guideline Addresses Specifics of HPV-Associated Oropharyngeal Cancer

5.

Taking the "Boob Bus"; Reluctance to Grant Prior Authorization; Alcohol's Carcinogenic Potential?


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot